



OFFICERS

President

Kelly J. Clark, MD, MBA, DFAPA, DFASAM

President-Elect

Paul H. Earley, MD, DFASAM

Vice President

Margaret Jarvis, MD, DFASAM

Secretary

Yngvild Olsen, MD, MPH, DFASAM

Treasurer

Brian Hurley, MD, MBA, FASAM

Immediate Past President

R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM

October 9, 2018

The Honorable Ann Kuster
U.S. House of Representatives
137 Cannon House Office Building
Washington, DC 20515

BOARD OF DIRECTORS

Directors-at-Large

Anthony Albanese, MD, DFASAM

Marc Galanter, MD, DFASAM

William F. Haning, III, MD, DFAPA, DFASAM

Petros Levounis, MD, MA, DFASAM

John C. Tanner, DO, DFASAM

**Re: The Humane Corrections Healthcare Act (HR 6764) & The
Corrections Public Health and Community Re-Entry Act**

Dear Representative Kuster,

On behalf of the American Society of Addiction Medicine (ASAM), the nation's oldest and largest medical specialty society representing more than 6,100 physicians and allied health professionals who specialize in the prevention and treatment of addiction, I am writing to extend ASAM's support for the following bills: the Humane Corrections Healthcare Act and the Correctional Healthcare and Re-Entry Act.

The risk of opioid-related overdose death dramatically increases in the first days and weeks after an individual with untreated opioid use disorder is released from jail or prison.ⁱ Providing treatment access during incarceration and warm handoffs to community-based care upon release can reduce this risk and help save lives. A recent joint policy statement by ASAM and the American Correctional Association (ACA) recommends that all individual detainees at jails and prisons should be screened for opioid use disorder (OUD) and that addiction treatment medications, behavioral health treatment, and support services should be considered for all individuals with OUD, as outlined in *The National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use*.ⁱⁱ Passing legislation to increase access to evidence-based addiction treatment, including the use of medications, and facilitate the connections to community-based care for individuals released from the criminal justice system is a key part of a comprehensive Congressional response to the ongoing opioid overdose epidemic.

Our prisons and jails do not have the capacity to meet the needs of the growing inmate population suffering from untreated substance use disorder. Thus, we appreciate your leadership in introducing these two important bills which would extend Medicaid eligibility to inmates of public institutions and create a new grant to provide funding for state, county, and municipal jails and prisons to increase the utilization of

Regional Directors

Region I Director

Jeff Selzer, MD, DFASAM

Region II Director

Murtuza Ghadiali, MD

Region III Director

Kenneth Freedman, MD, MS, MBA, FACP, AGAF, DFASAM

Region IV Director

Michael Shore, MD, DFASAM, DLFAPA

Region V Director

Anika Alvanzo, MD, MS, FACP, FASAM

Region VI Director

Gavin Bart, MD, PhD, DFASAM

Region VII Director

A. Kenison Roy, III, MD, DLFAPA, DFASAM

Region VIII Director

Miriam Komaromy, MD, FACP, DFASAM

Region IX Director

Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM

Region X Director

Scott Teitelbaum, MD, DFASAM

Ex-Officio

Stuart Gitlow, MD, MPH, MBA, DFAPA, DFASAM

Randolph P. Holmes, MD, FASAM

Michelle Lofwall, MD, FASAM

Penny S. Mills, MBA

Aleksandra Zgierska, MD, PhD

FOUNDING PRESIDENT

Ruth Fox, MD

1895-1989

addiction treatment medications and ensure a continuity of care for individuals after release from incarceration.

Thank you for your continued leadership. We look forward to working with you to advance these two important pieces of legislation that will increase access to addiction treatment and reduce overdose deaths.

Sincerely,

A handwritten signature in black ink that reads "Kelly J. Clark". The signature is written in a cursive, flowing style.

Kelly J. Clark, MD, MBA, DFASAM
President, American Society of Addiction Medicine

ⁱ Binswanger IA, Blatchford PJ, Mueller SR, and Stern MF. Mortality After Prison Release: Opioid Overdose and Other Causes of Death, Risk Factors, and Time Trends From 1999 to 2009. *Ann Intern Med* 2013 Nov 5; 159(9): 592–600.

ⁱⁱ ASAM. National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use (ASAM, 2015).